Cat: HF-2029
Cat: HF-2029
IFNA2, Human, HEK293 Cells,Tag Free: Product Information
V00549
Human embryonic kidney cell, HEK293-derived human IFN-alpha A protein
Cys24-Glu188
19.2 kDa
Solution protein.
Dissolved in sterile PBS buffer. This solution can be diluted into other aqueous buffers. Centrifuge the vial prior to opening.
Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage. 12 months from date of receipt, -20 to -70 °C as supplied.
Shipping with dry ice.
> 95%, determined by SDS-PAGE.
<0.010 EU per 1 ug of the protein by the LAL method.
Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus(VSV). The EC50 for interferon in this assay is 0.5-3 pg/mL.
IFNA2, Human, HEK293 Cells,Tag Free:SDS-PAGE & Bioactivity
IFNA2, Human, HEK293 Cells,Tag Free:Synonyms
Human IFNA2; IFNA2a; IFNalpha 2; IFN-alpha 2; IFN-alphaA; INFA2; interferon alpha A
IFNA2, Human, HEK293 Cells,Tag Free:Background
Interon-alpha (IFN-alpha), also known as leukocyte interferon, represents a group of related but distinct proteins that share over 95% amino acid
sequence homology. They are members of the type I interferon family which share a common cell surface receptor composed of two subunits, a 100 kDa ligand-binding subunit (IFN-alpha R2) and a 125 kDa ligand binding and signal transduction subunit (IFN-alpha R1) that is involved both in ligand bindingand signal transduction (1, 2). IFN-alpha has both anti-viral and immunomodulatory activities on target cells. Type I Interferons (IFNs) are well-known
cytokines that exert antiviral activity, antitumor activity, and immunomodulatory effects. Interferon tau (IFNT), a type I IFN similar to alpha IFNs (IFNA), is the pregnancy recognition signal produced by the ruminant conceptus. Among the IFN-α genes, a total of 28 different sequence variants have been
described. The three principal subtypes of IFNα-2 are designated α-2a, α-2b, and α-2c. IFNα-2b is being the predominant allele while IFNα-2a is less predominant and IFNα-2c only a minor allelic variant (2, 3).
1. Wang. et al. (2004) J Neuroimmunol. 156(1-2): 107-12.
2. Groopman JE, et al. (1984) Ann Intern Med. 100(5): 671-6.
3. Krueger JM, et al. (1987) Int J Immunopharmacol. 9(1): 23-30.